Minimal clinical impact of embolization to new territory on outcomes in medium vessel occlusion strokes treated with mechanical thrombectomy: a retrospective multicenter study.

医学 栓塞 闭塞 多中心研究 回顾性队列研究 冲程(发动机) 外科 放射科 随机对照试验 机械工程 工程类
作者
Hamza Salim,Vivek Yedavalli,Dhairya A. Lakhani,Fathi Milhem,Basel Musmar,Nimer Adeeb,Tobias D. Faizy,Motaz Daraghma,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Inayat Grewal,Leonard L.L. Yeo,Benjamin Yong‐Qiang Tan,Robert W. Regenhardt,Jeremy J. Heit
出处
期刊:PubMed
标识
DOI:10.1136/jnis-2024-022570
摘要

Mechanical thrombectomy (MT) is established as an effective treatment for large vessel occlusion strokes, but its efficacy and safety for medium vessel occlusions (MeVOs) remain less clear. This study examines the impact of periprocedural embolization to a new vascular territory (ENT) on clinical outcomes in patients with MeVO stroke treated with MT. A multicenter, retrospective analysis was conducted using the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry, including 2122 patients with MeVO stroke w-ho underwent MT between September 2017 and July 2023. ENT was defined as filling defects in previously unaffected territories, excluding embolization near the original occlusion, observed on final angiographic runs after retrieval of the primary thrombus. The associations between ENT, procedural variables, and 90-day clinical outcomes were evaluated, including functional independence (modified Rankin Scale (mRS) scores of 0-2), excellent outcomes (mRS 0-1), mortality, and hemorrhagic complications. ENT occurred in 2.9% (63/2122) of patients. Longer onset-to-arterial puncture time (adjusted OR 1.03; 95% CI 1.01 to 1.05; P=0.002) and a greater number of passes (adjusted OR 1.15; 95% CI 1.01 to 1.32; P=0.032) were associated with increased ENT risk, while excellent recanalization (thrombolysis in cerebral infarction (TICI) scale score 2c-3) was associated with reduced ENT risk (adjusted OR 0.41; 95% CI 0.23 to 0.72; P=0.002). ENT was not associated with poorer functional independence, mortality, or hemorrhagic complications. ENT during MT for MeVO stroke occurs infrequently and does not significantly affect the clinical outcomes. These findings suggest ENT risk should not deter clinicians from performing MT in patients with MeVO. Further prospective studies are needed to validate these results.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tjh发布了新的文献求助10
1秒前
1秒前
Yazoo完成签到,获得积分10
1秒前
gavin发布了新的文献求助30
1秒前
乐乐应助唐糖采纳,获得10
2秒前
Chr15发布了新的文献求助10
2秒前
yw发布了新的文献求助10
3秒前
领导范儿应助caixk采纳,获得10
4秒前
Gpu_broken应助席成风采纳,获得10
4秒前
cassie完成签到,获得积分10
4秒前
888关闭了888文献求助
4秒前
5秒前
睡个懒觉完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
充电宝应助故然采纳,获得10
7秒前
斯文翠完成签到,获得积分20
9秒前
Hello应助无私世界采纳,获得10
9秒前
9秒前
Ava应助酷炫的世倌采纳,获得10
10秒前
端庄的飞阳完成签到,获得积分10
11秒前
无心的莛发布了新的文献求助10
11秒前
菲菲发布了新的文献求助30
11秒前
11秒前
彭于晏应助許1111采纳,获得10
11秒前
思源应助甜甜采纳,获得10
12秒前
科研通AI6.4应助遥知马采纳,获得10
14秒前
15秒前
15秒前
斯文翠发布了新的文献求助10
15秒前
苹果千筹完成签到,获得积分10
17秒前
17秒前
18秒前
强强完成签到,获得积分10
19秒前
久违完成签到,获得积分10
19秒前
星星赶路完成签到,获得积分10
20秒前
科研通AI6.2应助suusu采纳,获得10
20秒前
20秒前
年轻问柳发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Picture this! Including first nations fiction picture books in school library collections 1500
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
Rheumatoid arthritis drugs market analysis North America, Europe, Asia, Rest of world (ROW)-US, UK, Germany, France, China-size and Forecast 2024-2028 500
17α-Methyltestosterone Immersion Induces Sex Reversal in Female Mandarin Fish (Siniperca Chuatsi) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6365562
求助须知:如何正确求助?哪些是违规求助? 8179494
关于积分的说明 17241781
捐赠科研通 5420542
什么是DOI,文献DOI怎么找? 2868024
邀请新用户注册赠送积分活动 1845232
关于科研通互助平台的介绍 1692636